Superworth

Macrogenics free cash flow MGNX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2012.

Last 12 months, to Jun 30, 2026
−$65.5M
Latest quarter, Q2 FY26
−$41.6M
Fiscal year 2025
−$83M

Macrogenics' free cash flow was −$65.5M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$41.6M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$83Mn/a
FY2024−$72.1Mn/a
FY2023−$80Mn/a
FY2022−$90.6Mn/a
FY2021−$150Mn/a
FY2020−$117.8Mn/a
FY2019−$138.6Mn/a
FY2018−$178.2Mn/a
FY2017−$15Mn/a
FY2016−$55.1Mn/a
FY2015−$22.9Mn/a
FY2014−$36.3Mn/a
FY2013−$17.1Mn/a
FY2012n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$41.6Mn/a−$65.5M
Q1 FY26−$36.2Mn/a−$71.7M
Q4 FY25$42.8Mn/a−$83M
Q3 FY25−$30.6M−151%−$164.8M
Q2 FY25−$47.7Mn/a−$74.6M
Q1 FY25−$47.4Mn/a−$72.4M
Q4 FY24−$39Mn/a−$72.1M
Q3 FY24$59.6Mn/a−$61.7M
Q2 FY24−$45.5Mn/a−$157M
Q1 FY24−$47.1Mn/a−$113.9M
Q4 FY23−$28.7M−199%−$80M
Q3 FY23−$35.7Mn/a−$22.4M

Against its peers

Companies in Drug Manufacturers - General nearest Macrogenics' size, closest first, today.

CompanyFree cash flow yield
MGNXMacrogenics−45.7%
NATRNatures Sunshine Products8.5%
LFVNLifevantage9.1%
SPROSpero Therapeuticsn/m
ATNMActinium Pharmaceuticalsn/m
ARVNArvinas−43.7%
PBYIPuma Biotechnology7.2%
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics5.6%
CRMDCorMedixn/m
COLLCollegium Pharmaceuticaln/m
Peer median7.2%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Macrogenics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.